Mineral and Electrolyte Disorders With SGLT2i Therapy-Reference-Cited by-同舟云学术

Mineral and Electrolyte Disorders With SGLT2i Therapy

Published:2019-11 Issue:11 Volume:3 Page:
ISSN:2473-4039
Container-title:JBMR Plus
language:en
Short-container-title:JBMR Plus

Author:

Cianciolo Giuseppe¹,De Pascalis Antonio²,Capelli Irene¹,Gasperoni Lorenzo¹,Di Lullo Luca³,Bellasi Antonio⁴^ORCID,La Manna Gaetano¹^ORCID

Affiliation:

1. Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Transplantation Unit, St. Orsola Hospital University of Bologna Bologna Italy

2. Department of Nephrology and Dialysis V. Fazzi Hospital Lecce Italy

3. Department of Nephrology and Dialysis Parodi‐Delfino Hospital Colleferro Italy

4. Department of Research Innovation and Brand Reputation, ASST Papa Giovanni XXIII Bergamo Italy

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbm4.10242

Reference61 articles.

1. SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome

2. Emerging drugs for chronic kidney disease

3. Mechanisms and Treatment of CKD

4. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

5. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits;Cellular Signalling;2024-10

2. Could the administration of SGLT2i agents serve as a viable prophylactic approach against CNI-induced toxicities?;Medical Hypotheses;2024-08

3. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression;Expert Opinion on Drug Safety;2024-07-08

4. The clinical efficacy, outcomes and quality of life of diabetic disease patients treated with dapagliflozin;Medicover Journal of Medicine;2024-04

5. SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes;Renal Replacement Therapy;2024-01-31